(Q38121995)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Frank P Vendetti

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

17 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1273-1285

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

DNA hypomethylation in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Increased methylation variation in epigenetic domains across cancer types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Evidence for an instructive mechanism of de novo methylation in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetic stem cell signature in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A DNA hypermethylation module for the stem/progenitor cell signature of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A decade of exploring the cancer epigenome - biological and translational implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Gene-promoter hypermethylation as a biomarker in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

DNA methylation markers and early recurrence in stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Rethinking how DNA methylation patterns are maintained

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

CpG methylation is maintained in human cancer cells lacking DNMT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

De novo CpG island methylation in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Interplay between microRNAs and the epigenetic machinery: an intricate network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Histone deacetylase 1 mRNA expression in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Dnmt3a is essential for hematopoietic stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Human DNA methylomes at base resolution show widespread epigenomic differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Chromatin organization is a major influence on regional mutation rates in human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2'deoxycytidine-induced cytotoxicity in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Targeting DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetics as a mechanism driving polygenic clinical drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

Epigenetic resensitization to platinum in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.819337

10.1517/14712598.2013.819337

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference